iRhythm Technologies (NASDAQ:IRTC) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Key Points

• Needham & Company LLC raised its price target on iRhythm from $254 to $255 and kept a "buy" rating, implying about a 97.43% upside from the current share price.
• Q1 beat: iRhythm posted EPS of ($0.35) vs. consensus ($0.66) and revenue of $199.4M (up 25.6% YoY), while issuing full-year revenue guidance of $875M–$885M roughly in line with expectations.
• Analyst sentiment is mixed but skewed positive (consensus "Moderate Buy" with a $203.77 target), while company insiders sold roughly $12.7M of stock last quarter.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) had its price target increased by equities research analysts at Needham & Company LLC from $254.00 to $255.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. Needham & Company LLC's price objective points to a potential upside of 97.43% from the company's current price.

IRTC has been the subject of several other research reports. Freedom Capital raised shares of iRhythm Technologies to a "strong-buy" rating in a research report on Thursday, January 15th. Truist Financial decreased their target price on shares of iRhythm Technologies from $200.00 to $170.00 and set a "buy" rating for the company in a research report on Wednesday, April 15th. Wells Fargo & Company decreased their target price on shares of iRhythm Technologies from $225.00 to $200.00 and set an "overweight" rating for the company in a research report on Friday, February 20th. Wall Street Zen downgraded shares of iRhythm Technologies from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Finally, Robert W. Baird decreased their target price on shares of iRhythm Technologies from $220.00 to $200.00 and set an "outperform" rating for the company in a research report on Friday, February 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $203.77.

iRhythm Technologies Stock Up 7.0%

Shares of IRTC stock opened at $129.16 on Friday. The firm has a fifty day moving average of $122.93 and a 200-day moving average of $154.60. The company has a quick ratio of 4.48, a current ratio of 4.63 and a debt-to-equity ratio of 4.25. iRhythm Technologies has a 12-month low of $105.62 and a 12-month high of $212.00. The company has a market capitalization of $4.24 billion, a price-to-earnings ratio of -92.26 and a beta of 1.18.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.31. iRhythm Technologies had a negative net margin of 5.96% and a negative return on equity of 28.15%. The company had revenue of $199.39 million during the quarter, compared to the consensus estimate of $194.11 million. During the same quarter in the prior year, the firm earned ($0.97) earnings per share. The firm's revenue was up 25.6% compared to the same quarter last year. As a group, equities research analysts predict that iRhythm Technologies will post -0.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Sumi Shrishrimal sold 6,217 shares of the firm's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $135.42, for a total value of $841,906.14. Following the completion of the transaction, the executive vice president owned 39,182 shares of the company's stock, valued at approximately $5,306,026.44. This trade represents a 13.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Quentin S. Blackford sold 25,540 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $135.42, for a total transaction of $3,458,626.80. Following the completion of the sale, the chief executive officer owned 186,126 shares of the company's stock, valued at approximately $25,205,182.92. This represents a 12.07% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 94,509 shares of company stock valued at $12,734,195 in the last quarter. Company insiders own 1.10% of the company's stock.

Institutional Trading of iRhythm Technologies

A number of large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in iRhythm Technologies by 48.4% in the fourth quarter. GAMMA Investing LLC now owns 184 shares of the company's stock valued at $33,000 after acquiring an additional 60 shares during the last quarter. Ascent Group LLC lifted its stake in iRhythm Technologies by 0.7% in the fourth quarter. Ascent Group LLC now owns 9,587 shares of the company's stock valued at $1,701,000 after acquiring an additional 70 shares during the last quarter. WoodTrust Financial Corp lifted its stake in shares of iRhythm Technologies by 0.7% during the 4th quarter. WoodTrust Financial Corp now owns 10,070 shares of the company's stock worth $1,787,000 after buying an additional 70 shares during the last quarter. US Bancorp DE lifted its stake in shares of iRhythm Technologies by 7.8% during the 3rd quarter. US Bancorp DE now owns 1,042 shares of the company's stock worth $179,000 after buying an additional 75 shares during the last quarter. Finally, State of Wyoming lifted its stake in shares of iRhythm Technologies by 16.0% during the 4th quarter. State of Wyoming now owns 616 shares of the company's stock worth $109,000 after buying an additional 85 shares during the last quarter.

Trending Headlines about iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q1 beat on both EPS and revenue: iRhythm reported EPS of ($0.35) vs. consensus ($0.66) and revenue of $199.4M, up 25.6% year-over-year, showing demand recovery and top-line momentum. iRhythm Holdings Announces First-Quarter 2026 Financial Results
• Positive Sentiment: Management highlighted margin gains and market expansion opportunities, and commentators point to potential regulatory clarity and AI-driven efficiencies as medium-term tailwinds for unit economics. IRTC Q1 deep dive: Market expansion and margin gains amid regulatory and AI developments
• Neutral Sentiment: Full-year revenue guidance given at $875M–$885M (roughly in line with consensus ~ $876M), providing visibility but little upside surprise for FY26. View Press Release
• Neutral Sentiment: Investors can review the detailed Q1 earnings call for color on sales mix, commercial cadence, and cadence of AI investments — useful for judging how soon margins will normalize. iRhythm Holdings, Inc. (IRTC) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Truist cut its price target on IRTC as part of its MedTech preview, which may limit near-term upside as analysts reassess valuation and execution risk. Truist Cuts PT on iRhythm Technologies (IRTC) as Part of Fiscal Q1 Results Preview in MedTech
• Negative Sentiment: Company remains unprofitable (negative net margin and return on equity) despite the beat; EPS is still a loss and analysts expect negative FY earnings — a reminder that cash flow and profitability must improve to justify higher multiples. iRhythm Holdings, Inc. (IRTC) Reports Q1 Loss, Tops Revenue Estimates

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company's flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm's digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.